A British pharmaceutical services firm, Wasdell, has announced that it will be building a brand-new pharmaceutical facility in Dundalk, with Brexit being a factor in its relocation.
The €30 million testing-and-packaging facility will see 300 jobs created, including warehouse operatives, management, engineering and finance.
The facility will be a purpose built, 70,000 sq ft, self-contained site located at the IDA Dundalk Science and Technology Park. Wasdell Group, which is based in Swindon in the southwest of England, said the jobs would span five years.
Phase one of the build will occupy a 2.88 hectare site and represent an investment in excess of €30 million and will create 300 jobs. Wasdell also holds the land options to expand the site further with an additional 2.68 hectares.
The facility will offer QC import testing, a variety of current and novel packaging technologies as well as storage and distribution. The site will be operational by Q4 2018 and will incorporate serialisation technology in addition to bespoke customer manufacturing solutions.
The site will be their first outside of the UK and will allow them to continue servicing their customers’ requirements for import and release testing, the primary and secondary packing of the customers drug product as well as the distribution of such products into Europe as well as internationally. The building of the new facility will also provide their solution to a “hard” Brexit if this becomes a reality.
Martin Tedham, group managing director, stated, "We're delighted to have found such an ideal location for our new facility and a special thanks must be given to the Irish Government, the IDA as well as Louth County Council for their support in making our new site a reality. This is an exciting time for our business and will allow us to not only increase our capacity but also extend our operational footprint and the services we are able to offer our client base.”